AVIR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Atea Pharmaceuticals meets primary and secondary endpoints in the Phase 3 C-BEYOND North America hepatitis C trialJul 28, 2026
- Atea Pharmaceuticals initiated the first-in-human Phase 1 trial of AT-587 for hepatitis EJul 14, 2026
- Atea Pharmaceuticals announces full results from Phase 2 study of Bemnifosbuvir and Ruzasvir for treating Hepatitis C at EASL 2025.May 7, 2025